Frontline Targeted Therapy for METex14 Skip Mutation in NSCLC: Latest Updates from 2021

Learning ObjetivesKey Content Areas Include:

  1. Review METex14 skip mutation-driven lung cancer as an important subgroup with
    unmet needs.
  2. Discuss emerging targeted therapies in patients with METex14 skip mutations.
  3. Discuss latest 2021 clinical data for targeted therapies against METex14 skip
    mutations (ASCO/WCLC/ESMO 2021). 

Chair IconChair

Dr. Barbara Melosky

Speakers IconSpeakers

Dr. Johan Vansteenkiste

This program has been made possible through unrestricted support from Novartis.